GlassScriptPhysician profile
Kelli M Eglinger
NPI 1417926684
$2,257.57
in general payments reported to CMS, 2019-2025
23 companies · $548 in 2025
The $548 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $285 · 2022: $586 · 2023: $289 · 2024: $549 · 2025: $548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $580.10 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $419.94 | 2022-2025 | |
| Amgen INC. | $163.03 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.37 | 2021-2025 | Jardiance, Tradjenta |
| E.R. Squibb & Sons, L.L.C. | $150.97 | 2022-2023 | Eliquis |
| Exact Sciences Corporation | $125.22 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Novo Nordisk INC | $99.31 | 2021-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $86.62 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.95 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $75.98 | 2024-2025 | Voquezna |
| Pfizer INC. | $58.96 | 2023-2025 | |
| Lilly USA, LLC | $48.76 | 2023-2024 | Jardiance, Mounjaro |
| Esperion Therapeutics, INC. | $37.87 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $25.80 | 2021-2022 | |
| Biogen, INC. | $24.52 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $23.05 | 2025 | Shingrix |
| Novartis Pharmaceuticals Corporation | $21.19 | 2024 | |
| Alkermes, INC. | $20.81 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.00 | 2024 | |
| Abbott Laboratories | $13.70 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $13.30 | 2022 | |
| Grifols USA, LLC | $11.74 | 2021 | |
| Mylan Specialty L.P. | $11.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelli Eglinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.